Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001377577 | SCV001574947 | pathogenic | MPI-congenital disorder of glycosylation | 2023-08-16 | criteria provided, single submitter | clinical testing | This variant disrupts a region of the MPI protein in which other variant(s) (p.Ile398Thr) have been determined to be pathogenic (PMID: 10484808, 30545931). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 1066557). This variant has not been reported in the literature in individuals affected with MPI-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Ala363Hisfs*9) in the MPI gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 61 amino acid(s) of the MPI protein. |
Baylor Genetics | RCV001377577 | SCV004193721 | likely pathogenic | MPI-congenital disorder of glycosylation | 2022-11-03 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001377577 | SCV005633275 | likely pathogenic | MPI-congenital disorder of glycosylation | 2024-02-21 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001377577 | SCV002089792 | likely pathogenic | MPI-congenital disorder of glycosylation | 2020-07-21 | no assertion criteria provided | clinical testing |